Pharmaceuticals

Primary Biliary Cholangitis Therapeutics Market Forecast Through 2030 With Insights On Market Patterns And Developments

May 4, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

By 2030, What Market Size Is The Primary Biliary Cholangitis Therapeutics Market Expected To Reach Based On Its 2026 Value?

The primary biliary cholangitis therapeutics market size has experienced rapid growth in recent years. This market is projected to expand from $1.01 billion in 2025 to $1.14 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 12.9%. Historically, this growth can be attributed to factors such as limited treatment options for PBC, a growing prevalence of autoimmune liver diseases, increasing liver disease awareness campaigns, the widespread reliance on ursodeoxycholic acid monotherapy, and the expansion of hospital infrastructure dedicated to liver disease care.

The primary biliary cholangitis therapeutics market is projected to experience substantial expansion in the coming years, reaching a valuation of $1.85 billion by 2030, driven by a compound annual growth rate (CAGR) of 12.9%. This anticipated growth during the forecast period is fueled by several factors, including advancements in obeticholic acid and various combination therapies, an increase in investigational drugs and promising pipeline candidates, the wider acceptance of receptor agonists and modulators, greater patient awareness alongside early diagnosis efforts, and the expanding reach of online and retail pharmacy distribution channels. Key trends anticipated during this period encompass the increasing use of ursodeoxycholic acid and obeticholic acid treatments, the proliferation of combination therapies and pipeline medications, a stronger emphasis on prompt diagnosis and consistent disease monitoring, the broadening of hospital and retail pharmacy distribution channels, and enhanced public awareness regarding autoimmune liver diseases and patient education initiatives.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25887&type=smp

Which Factors Are Influencing The Growth Of The Primary Biliary Cholangitis Therapeutics Market?

The primary biliary cholangitis therapeutics market is anticipated to expand due to the rising occurrence of liver diseases. Liver diseases encompass various ailments that hinder normal liver function, frequently resulting in inflammation, fibrosis, or hepatic failure. This surge in liver disease cases stems from increased alcohol consumption, where excessive intake harms liver cells, causing inflammation and persistent liver issues. These therapeutics for primary biliary cholangitis assist in managing liver ailments by targeting bile duct inflammation, thereby decelerating disease advancement and maintaining liver function. They contribute to better patient results through symptom reduction, improved quality of life, and postponing the necessity for liver transplantation. For example, the Centers for Disease Control and Prevention (CDC), a US-based federal public health agency, reported in September 2025 that chronic liver disease and cirrhosis accounted for 52,222 deaths in the United States in 2023, positioning it as the ninth leading cause of death. Consequently, the growing incidence of liver diseases is a significant impetus for the expansion of the primary biliary cholangitis therapeutics market.

How Is The Primary Biliary Cholangitis Therapeutics Market Broken Down By Segment Categories?

The primary biliary cholangitis therapeutics market covered in this report is segmented –

1) By Drug: Ursodeoxycholic Acid, Obeticholic Acid, Other Drugs

2) By Mechanism Of Action (MOA): Receptor Agonist, Receptor Modulator, Enzyme Activator, Enzyme Inhibitor, Other Mechanisms Of Action

3) By Distribution Channel: Hospital Pharmacies, Drug Store And Retail Pharmacies, Online Pharmacies

4) By Use: Human, Veterinary

Subsegments:

1) By Ursodeoxycholic Acid: Branded Ursodeoxycholic Acid, Generic Ursodeoxycholic Acid, Combination Therapies With Ursodeoxycholic Acid

2) By Obeticholic Acid: Monotherapy, Combination Therapy, Branded Obeticholic Acid

3) By Other Drugs: Fibrates, Budesonide, Immunosuppressants, Investigational Drugs Or Pipeline Candidates

Which Trends Are Shaping The Primary Biliary Cholangitis Therapeutics Market?

Leading firms within the primary biliary cholangitis therapeutics market are dedicating efforts to developing innovative products and securing necessary approvals, such as for peroxisome proliferator-activated receptor agonists, with the goal of enhancing bile acid metabolism and decelerating disease progression in patients. Peroxisome proliferator-activated receptor (PPAR) agonists are pharmaceuticals designed to activate PPAR proteins, which in turn regulate genes instrumental in metabolism, inflammation, and energy balance. For example, in August 2024, Gilead Sciences Inc., a US-based pharmaceutical company, obtained accelerated approval from the U.S. Food and Drug Administration (FDA) for Livdelzi (seladelpar). This approval is for the treatment of primary biliary cholangitis (PBC) in adults who have shown an insufficient response to ursodeoxycholic acid (UDCA) or are unable to tolerate UDCA. Livdelzi is an oral, selective PPARd agonist that operates by activating the PPARd receptor to modulate genes associated with reducing liver inflammation, improving bile acid metabolism, and slowing the advancement of primary biliary cholangitis (PBC).

Which Players Are Present In The Primary Biliary Cholangitis Therapeutics Market Space?

Major companies operating in the primary biliary cholangitis therapeutics market are Novartis AG, Gilead Sciences Inc., Ipsen Pharma, Intercept Pharmaceuticals, Enanta Pharmaceuticals, Mirum Pharmaceuticals, Calliditas Therapeutics AB, Dr. Falk Pharma GmbH, NGM Biopharmaceuticals Inc., COUR Pharmaceuticals, HighTide Therapeutics Inc., Pliant Therapeutics Inc., Tiziana Life Sciences, Phenex Pharmaceuticals, Synlogic Therapeutics

Get The Full Primary Biliary Cholangitis Therapeutics Market Report:

https://www.thebusinessresearchcompany.com/report/primary-biliary-cholangitis-therapeutics-global-market-report

Which Region Has The Greatest Market Share In The Primary Biliary Cholangitis Therapeutics Market?

North America was the largest region in the primary biliary cholangitis therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the primary biliary cholangitis therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Primary Biliary Cholangitis Therapeutics Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/primary-biliary-cholangitis-therapeutics-global-market-report

Browse Through More Reports Similar to the Global Primary Biliary Cholangitis Therapeutics Market 2026, By The Business Research Company

Primary Biliary Cholangitis Market Report 2026

https://www.thebusinessresearchcompany.com/report/primary-biliary-cholangitis-global-market-report

Liver Diseases Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/liver-diseases-therapeutics-global-market-report

Cholinergic Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/cholinergic-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795